St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
NCT Number: NCT04362995
This is a prospective adaptive cohort study of St. Jude employees to determine the rate of SARS-CoV-2 infections that are asymptomatic and to evaluate immunological responses to SARS-CoV-2 infection.
Primary Objectives
* To estimate the proportion of asymptomatic infection with SARS-CoV-2 infection in a population of SARS-CoV-2-naïve adult St. Jude employees * To comprehensively map CD4 and CD8 T cell epitopes and response magnitudes to SARS-CoV-2 infection in a population of SARS-CoV-2-naïve adult St. Jude employees who acquire SARS-CoV-2 infection * To measure changes in the CD4 and CD8 response magnitude and function to SARS-CoV-2 infection and/or vaccination in a population of St. Jude employees for up to 48 months after infection and/or vaccination.
Secondary Objectives
* To establish seroprevalence of SARS-CoV-2-specific antibodies at baseline, and identify the rate of seroconversion to SARS-CoV-2 in a population of presumably naïve adult St. Jude employees * To identify features of T cell responses at baseline and during SARS-CoV-2 infection that are associated with protection against symptomatic or severe COVID-19 disease in a population of adult St. Jude employees * To identify risk factors for long-term protection against COVID-19 in a population of adult St. Jude employees * To evaluate changes in antibody responses to SARS-CoV-2 in a population of St. Jude employees for up to 48 months after SARS-CoV-2 infection and/or vaccination. * To evaluate the saliva antibody and cytokine response to SARS-CoV-2 infection and/or vaccination and identify characteristics that predict protection from subsequent SARS-CoV-2 infection among a population of St. Jude employees followed for up to 48 months after SARS-CoV-2 infection and/or vaccination. * To measure changes in saliva antibody responses to SARS-CoV-2 for up to 48 months after SARS-CoV-2 infection and/or vaccination.
Exploratory Objectives
* To establish additional immunological features including host immune or receptor polymorphisms associated with response to SARS-CoV-2 infection * To explore SARS-CoV-2 diversity and specific features in a circumscribed population * To describe the presence, characteristics, and proportion of short-term re-infection * To determine if an association between SARS-CoV-2 viral load in nasal swab specimens and COVID-19 symptoms can be identified in a population of adult St. Jude employees who acquire SARS-CoV-2 * To explore the laboratory and clinical response to SARS-CoV-2 vaccine in a population of adult St. Jude employees with and without a history of SARS-CoV-2 infection
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Memphis, Tennessee, 38105, United States
Naive individuals will contribute a baseline blood sample at enrollment. Subsequent routine blood draws will occur to determine the proportion of participants who have asymptomatically seroconverted; the timing of these blood draws and proportion of participants required will be determined by the rate of documented SARS-CoV-2 infection in the cohort according to an adaptive study design. Participants will be tracked for SARS-CoV-2 specific antibodies and CD4, and CD8 T cell responses throughout the period and especially during the early stages after clearance of infection and subsequently to determine the quality and duration of memory responses.
In addition to blood samples, participants will intermittently provide nasal swabs for detection of SARS-CoV-2; this will occur either through a comprehensive proactive employee screening program, or specifically for the purposes of the research study if participants are required to attend campus but are not currently eligible for employee screening. These will determine duration and characteristics of viral shedding and identify reinfection. Seroprevalence estimates and asymptomatic conversion will also be determined.
Individuals with a diagnosis of COVID-19 infection will have two additional blood draws in the acute and convalescent phase to identify acute and late immune responses. These responses will be compared to the essential baseline sample data to characterize the generation of de novo and cross-reactive recall responses.
For those participants receiving vaccination, blood draws will be taken after COVID vaccine (3-8 weeks after completion of 1 or 2 dose course) and at completion of study.
At enrollment, subjects will complete a baseline online personal health and demographic questionnaire, and then monthly brief online health update questionnaires. Throughout the study period, subjects will complete a brief online symptom survey every 2 weeks.
Participants in the original SJTRC study will be asked to reconsent to complete a one-time questionnaire regarding their COVID-19 experience specifically during the time since they went off study. Once this questionnaire is complete, they will be taken off study and receive no further questionnaires related to the original study.
A subset of participants will be invited to re-enroll in a long-term follow-up phase to evaluate long-term immunity and protection against COVID-19 following infection and vaccination. Participants will provide blood samples every 6 months. They will also be invited to provide additional acute and convalescent samples (blood and saliva), if diagnosed with acute COVID-19 during this period. Participants will continue to complete regular questionnaires, but the frequency will decrease to 6 monthly (health questionnaires) and as needed (COVID-19 diagnosis or vaccination).
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for LTFU arm:
Exclusion criteria
Exclusion criteria
for LTFU arm:
Time frame: 1 year from enrollment
The proportion of participants who test positive for SARS-CoV-2 infection but remain asymptomatic.
Time frame: at enrollment, 3 months, 6 months, 9 months and 1 year
A list of CD4 and CD8 cell epitopes with a magnitude change from baseline that is at least twice the standard deviation of the baseline.
Time frame: up to 48 months of additional observation in participants who have had COVID-19 or vaccination
A list of CD4 and CD8 cell epitopes with a magnitude change from baseline that is at least twice the standard deviation of the baseline.
Time frame: Baseline, 3 months, 6 months, 9 months and 1 year
The proportion of participants at each time point who have detectable antibodies that recognize SARS-COV-2.
Time frame: Baseline, 3 months, 6 months, 9months, 1 year and 6 monthly for an additional 48 months in participants included in the long-term follow-up arm
For CD8s, T cell responses will be categorized as cytolytic, cytokine producing, or exhausted. For CD4s they will be grouped as Th1, Th2, Tfh, or Th17. Percentages of cells in each category will be summarized at baseline and during SARS-CoV-2 infection.
Time frame: up to 48 months of additional observation in participants who have had COVID-19 or vaccination
For participants who have enrolled in the long-term follow-up arm of the study, associations between persistent protective antibody responses and clinical and laboratory characteristics will be evaluated by paired tests and regression models.
Time frame: up to 48 months of additional observation in participants who have had COVID-19 or vaccination
For participants who have enrolled in the long-term follow-up arm of the study, changes in antibody levels from baseline in paired samples.
Time frame: up to 48 months of additional observation in participants who have had COVID-19 or vaccination
For participants who have enrolled in the long-term follow-up arm of the study, changes in saliva antibody and cytokine levels from baseline.
St. Jude Children's Research Hospital
Other
SJTRC-St. Jude Tracking of Viral and Host Factors Associated With COVID-19: A Prospective Adaptive Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04335084
COVID, COVID-19
Ventura, California, United States
View Trial DetailsNCT04690413
COVID-19, Coronaviridae Infections
Tucson, Arizona, United States
View Trial DetailsNCT04363268
COVID, COVID-19
Palo Alto, California, United States
View Trial DetailsNCT04449276
COVID-19, Coronaviridae Infections
Ghent, Belgium
View Trial Details